Orthopaedic Sports Medicine BPC-157

Orthopaedic Sports Medicine BPC-157

Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries. Despite lacking US Food and Drug Administration approval and its use being banned in professional sports, it is increasingly used by clinicians and athletes. Purpose: We sought to (1) provide a comprehensive synthesis of the BPC-157 literature from an orthopaedic sports medicine perspective and (2) elucidate the mechanism of action, musculoskeletal effects, metabolism, and safety profile.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It was originally studied as a peptide associated with gastric tissue and has attracted attention because laboratory and animal studies suggest it may influence tissue repair, inflammation, blood vessels, and the gastrointestinal system. It is sometimes promoted online for muscle, tendon, ligament, joint, and digestive problems.

However, an important distinction is that most of the evidence for BPC-157 comes from laboratory and animal research, not high-quality human clinical trials. A 2025 systematic review identified 36 relevant studies, but 35 were preclinical, and only one was a clinical study.

Potential Benefits of BPC-157

Research has suggested several possible effects

Muscle and tendon healing
Animal studies indicate that BPC-157 may support healing of injured muscles, tendons, and ligaments. Researchers have proposed that it may influence pathways involved in blood-vessel formation, collagen production, and tissue repair.

Joint and connective-tissue recovery
BPC-157 has received particular attention in sports medicine. One small retrospective human study involving people with chronic knee pain reported that 7 of 12 patients experienced relief lasting more than six months after an intra-articular injection. However, this was not a large randomised clinical trial, so it cannot establish that BPC-157 caused the improvement.

Anti-inflammatory effects
Preclinical research suggests BPC-157 may reduce certain inflammatory signals. This has led researchers to investigate its possible role in tissue injuries and inflammatory conditions. These effects, however, have not been adequately demonstrated as clinical benefits in humans.

Gastrointestinal protection
BPC-157 has been investigated in experimental models involving intestinal injury and inflammatory gastrointestinal conditions. This is one reason it is sometimes marketed for digestive health. Nevertheless, there is not enough human evidence to establish it as an effective treatment for gastrointestinal disease.

Possible Side Effects and Risks

The biggest problem with BPC-157 is not that researchers have proven it to be highly toxic; rather, we do not yet know enough about its long-term safety.

The U.S. Food and Drug Administration (FDA) reported in 2026 that available human studies were small and short and provided limited safety monitoring. The studies used different routes and doses, making it difficult to establish a reliable safety profile.

Reported adverse effects in limited studies have included headache and flatulence. A very small 2025 intravenous study involving only two people reported no side effects, but such a tiny study cannot establish safety for the general population.

There are also concerns about contamination, impurities, incorrect dosing, and immune reactions, particularly with products obtained from unregulated sources. The FDA has specifically raised concerns about immunogenicity and peptide-related impurities with compounded BPC-157 products.

If you’re asking me to review and correct this BPC-157 dosage section, the main issue is that it presents anecdotal doses as though they were established therapeutic doses. I would rewrite it more cautiously and accurately:

BPC-157 Dosage

There is currently no officially established therapeutic dose for BPC-157 in humans. BPC-157 is an investigational peptide and is not FDA-approved for treating medical conditions. Human clinical evidence remains very limited, so there is insufficient evidence to establish a standard dose, treatment duration, or preferred route of administration.

Some websites and peptide clinics describe doses such as 500–1,000 mcg per day orally or approximately 400–600 mcg per day by subcutaneous injection. However, these amounts are based largely on anecdotal reports and non-standardised protocols rather than adequately powered human clinical trials. They should not be considered medically established dosing recommendations.

Animal studies have investigated substantially different doses, including doses that would not be appropriate to directly translate to humans. For example, findings that a particular dose was tolerated in rodents do not establish that the same dose is safe or effective in humans.

There is also no good clinical evidence establishing that BPC-157 should be cycled, used continuously, or injected near an injured area. Claims that people can safely use BPC-157 for months or years are anecdotal and cannot establish long-term safety.

Important Safety Consideration

The major limitation is the lack of long-term human safety data. Potential concerns include unknown effects from prolonged exposure, immune reactions, impurities or contamination in compounded products, and uncertainty about the appropriate dose and route of administration.

Therefore, rather than presenting 500–1,000 mcg/day or 400–600 mcg/day as recommended doses, it is more accurate to describe them as reported experimental or anecdotal dosing ranges. A physician should be involved before considering an investigational peptide, particularly an injectable product.

There is currently no scientifically validated BPC-157 dosage for treating injuries, inflammation, gastrointestinal disease, or other medical conditions in humans. Rodent dosing cannot reliably be converted into a human therapeutic dose.

Bottom Line

BPC-157 is an experimental peptide with interesting regenerative and anti-inflammatory effects in laboratory and animal research, particularly involving muscles, tendons, ligaments, and gastrointestinal tissues. But the evidence is not yet strong enough to conclude that it safely or effectively treats these conditions in humans. Current clinical evidence is extremely limited, and there is no validated standard dosing regimen or approved pharmaceutical formulation.

Therefore, BPC-157 should be regarded as investigational rather than an established medical treatment. Anyone considering BPC-157—especially injectable or oral products purchased online—should discuss the risks and alternatives with a qualified physician rather than assuming that “peptide” means safe.